-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Announces BCX9930 Shows Clinical Benefit as Monotherapy Through 400 mg bid in Treatment-naive PNH Patients
-
-
-
-
-
-
-
BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock
-
-
-
-
-
-
-
BioCryst Pharmaceuticals Prices Public Offering of Common Stock
-
-
-
-
-
-
-
BioCryst Pharma (BCRX) Prices 15.53M Share Common Offering at $5.15/Sh
-
-
-
-
-
-
-
Pre-Open Movers 03/09: (APRI) (VVUS) (ELF) Higher; (TLRD) (SPPI) (RATE) Lower (more...)
-
-
-
-
-
72,267 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

